Kewalramani Reshma

CEO Kewalramani sells 40,000 VRTX shares across 13 transactions for $19.7M; post-trade holdings 98,278 shares.

Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals, executed 13 separate sales totaling 40,000 shares for $19,738,854.85, reducing holdings by -28.9% from 138,278 to 98,278 shares. The transaction prices ranged from $479.75 to $496.16, with a blended average of $493.47, occurring while the stock currently trades at $474.27 (-7.7% from its 52-week high of $513.76). At the same-ticker level, Kewalramani's prior 5 trades at VRTX showed a 5 of 5 well-timed pattern at the 90-day mark, with her most recent buys (2025-08-06) posting 90-day returns of +8.1% and +8.4%, while her three prior sells (2024-07-22, 2024-07-30, 2024-11-08) each generated negative 90-day returns of -2.8%, -5.7%, and -6.6% respectively. The fundamental backdrop shows Vertex with solid metrics: $3.1B latest quarterly revenue, $1.1B net income, +8.9% annual growth, and a P/E of 14.76 on a $120.5B market cap. The timing and magnitude of this disposition warrant attention given the insider's demonstrated precision in prior transactions at this ticker and the proximity of current price to the year's lows.

CEO Kewalramani purchases 10,000 shares at blended avg $389.58 as stock down 19.4% in 30 days

Kewalramani Reshma, CEO & President, executed 2 separate purchases totaling 10,000 shares for $3,895,767.70 on 2025-08-06 at a blended average price of $389.58, increasing her holdings by 9.4% to 116.0K shares. The timing occurs amid significant recent weakness: the stock has declined 19.4% over 30 days and stands 27.3% below its 52-week high of $516.74, currently trading at $375.63. At VRTX specifically, Kewalramani's prior trading record shows mixed timing outcomes: 3 of her 5 preceding sales at this ticker were well-timed at the 90-day mark. The company posted net income of $1,032,900,000.00 in the latest quarter on $2,964,700,000.00 revenue with 11.7% annual revenue growth, though full-year results show the company was unprofitable over its most recent complete fiscal year. The purchase size and timing relative to recent price deterioration merit observation.

VRTX CEO Kewalramani sells 15,198 shares at $515.00 for $7,826,970 on 2024-11-08; stock now $490.00.

Kewalramani, VRTX's CEO, executed a substantial open-market sale of 15,198 shares at $515.00 on 2024-11-08, representing a -16.7% reduction in her stake to 75,772 shares post-transaction. The sale occurred near the 52-week high of $516.74 and ahead of the current price of $490.00, which is -5.2% from that peak. Across her prior 5 trades at VRTX, her same-ticker timing pattern is mixed: two of five prior sells were well-timed at the 90-day mark, while three resulted in positive or mixed 90-day returns. Her broader cross-ticker track record shows 11 prior sells with an 18.18% well-timed rate, below the baseline, suggesting her historical sell timing does not constitute a strong directional signal. VRTX fundamentals remain solid—$2.8B quarterly revenue, $1.0B net income, and +10.5% annual revenue growth—with the company trading at 34.88 P/E and a $126.2B market cap, offering no obvious distress signal to explain the sale.

CEO Kewalramani sold 15,202 shares of VRTX at $505.00 on 2024-07-30; stock at 52-week high, prior same-ticker sells showed positive returns.

Kewalramani Reshma, CEO & President, sold 15,202 shares worth $7,677,010.00 at $505.00 per share on 2024-07-30, reducing her post-transaction holdings to 90,970 shares, a decrease of 14.3% from pre-transaction holdings of 106,172 shares. The stock currently trades at $505.78, nearly at its 52-week high of $505.78, and has gained 6.8% over 30 days and 26.1% over 90 days. Notably, Kewalramani's prior five trades at VRTX were all sells, and measurable outcomes show positive post-sale returns: her 2023-12-15 sale returned +6.5% in 30 days and +0.4% in 90 days; her 2023-12-13 sale returned +9.2% in 30 days and +3.9% in 90 days. At the cross-ticker level, her track record across 10 prior sells shows a 90-day well-timed rate of 0.00%, indicating her sales have historically not preceded stock declines. The execution occurs while the stock stands at an elevated valuation level with a P/E of 32.46 and a market cap of $130,518,242,076.86, though net income of $1,099,600,000.00 and annual revenue growth of +10.5% demonstrate underlying profitability.

Kewalramani (VRTX CEO) sold 15.2K shares at $497.00 on 2024-07-22; post-transaction holdings 106.2K shares (-12.5%)

Kewalramani Reshma, CEO & President of Vertex Pharmaceuticals, sold 15,202 shares for a total value of $7,555,394.00 at $497.00 per share, reducing her holdings by 12.5% to 106.2K shares post-transaction. At her prior trades at VRTX, the 90-day timing pattern shows 0 of 3 measurable sales were well-timed (stock rose after each sale), with average 90-day returns of +0.4% to +12.2%, indicating she has sold before upward moves. The current stock price of $490.80 is 1.0% below the transaction price and near the 52-week high of $495.91; the company has posted strong fundamentals with $2.7B quarterly revenue, $1.1B net income, and 10.5% annual revenue growth. The sale represents a material reduction in CEO holdings but occurs in a context of positive 90-day stock momentum (+23.4%) and near-peak valuations, without a clear pattern of downside-protective timing at this ticker.